This afternoon, the Australian Government released its response to the report of the Productivity Commission Inquiry into IP released 20 December 2016.
In its 25 page response...
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Naomi Pearce | Aug 25, 2017
This afternoon, the Australian Government released its response to the report of the Productivity Commission Inquiry into IP released 20 December 2016.
In its 25 page response...
By Bioblast Editor | Aug 24, 2017
Imraldi®, Biogen/Samsung’s adalimumab biosimilar approved in the EU.
By Naomi Pearce | Aug 22, 2017
Just over a week ago, the US Federal Circuit provided BPCIA “dance lessons” for reference product sponsors and biosimilar applicants, as it handed down its decision in Amgen v Hospi...
By Bioblast Editor | Aug 21, 2017
Sandoz launches Erelzi® in Canada.
By Bioblast Editor | Aug 16, 2017
Biocon/Mylan withdraw EU applications for biosimilar trastuzumab & pegfilgrastim.
By Bioblast Editor | Aug 02, 2017
AbbVie commences BPCIA proceedings against Boehringer Ingelheim for Humira® (adalimumab) biosimilar in the District Court of Delaware, alleging infringement of 8 patents: (8,926,975; 9,018,361; 9,090,867; 9,096,666; 9,255,143; 9,266,949; 9,272,041; and 9,546,212), a subset ...
By Naomi Pearce | Aug 01, 2017
The TGA consultation paper can be found here.
The TGA paper outlines the biosimilar naming conventions implemented in EU (INN), Japan (BSn), and the planned US 4 letter biolog...
By Bioblast Editor | Aug 01, 2017
Celltrion/Mundipharma claim their biosimilar rituximab (Truxima®) has 30% of total EU market due to rapid growth.
By Bioblast Editor | Aug 01, 2017
MSD’s biosimilar infliximab (Renflexis®), co-developed with Samsung Bioepis, is the second biosimilar to be PBS listed in Australia.
By Bioblast Editor | Jul 31, 2017
Amgen and Allergan announce BLA filing for ABP980, biosimilar trastuzumab.
SUBSCRIBE TO PEARCE IP